Cuozzo, Mariarosaria The microbiota-gut-brain axis: an emerging therapeutic target in chemotherapy-induced peripheral and central impairment. [Tesi di dottorato]
Anteprima |
Testo
Cuozzo_Mariarosaria_XXXVI_Cycle.pdf Download (3MB) | Anteprima |
| Tipologia del documento: | Tesi di dottorato |
|---|---|
| Lingua: | English |
| Titolo: | The microbiota-gut-brain axis: an emerging therapeutic target in chemotherapy-induced peripheral and central impairment. |
| Autori: | Autore Email Cuozzo, Mariarosaria mariarosaria.cuozzo@unina.it |
| Numero di pagine: | 151 |
| Istituzione: | Università degli Studi di Napoli Federico II |
| Dipartimento: | Farmacia |
| Dottorato: | Scienza del farmaco |
| Ciclo di dottorato: | 36 |
| Coordinatore del Corso di dottorato: | nome email Meli, Rosaria rosaria.meli@unina.it |
| Tutor: | nome email Russo, Roberto [non definito] Meli, Rosaria [non definito] |
| Numero di pagine: | 151 |
| Parole chiave: | microbiota; gut microbiota; dysbiosis; chemotherapy; sodium butyrate; probiotics; postbiotics; neuropathic pain; chronic pain; mood disorders; depression; anxiety; inflammation. |
| Settori scientifico-disciplinari del MIUR: | Area 05 - Scienze biologiche > BIO/14 - Farmacologia |
| Depositato il: | 18 Mar 2024 09:48 |
| Ultima modifica: | 09 Mar 2026 10:59 |
| URI: | http://www.fedoa.unina.it/id/eprint/15720 |
Abstract
Recent advancements in neuroscience have highlighted the intricate connection between the gut microbiota, gut health, and brain function, with implications for various health conditions ranging from stress-related disorders to neurodegenerative diseases. Intestinal dysbiosis, or the imbalance of gut microbiota, has been implicated in the pathophysiology of neuropathic pain and other neurological disorders. Chemotherapy has been linked to reduced levels of short-chain fatty acid (SCFA)-producing bacteria and decreased fecal and serum SCFA concentration, often accompanied by impaired gut barrier function. . Researchers are actively exploring interventions such as probiotics, prebiotics, and fecal microbiota transplantation to mitigate gut dysbiosis and its associated health effects. For instance, studies have shown that probiotic administration during chemotherapy may help improve bowel function by restoring microbiota diversity. Our study focuses on investigating paclitaxel (PTX)-induced dysbiosis and its correlation with peripheral and central manifestations such as neuropathic pain and associated mood disorders. We explored the therapeutic potential of probiotics, specifically SLAB51, in alleviating neuropathy symptoms and protecting against PTX-induced nerve damage. Additionally, we examined the role of sodium butyrate (BuNa), a postbiotic, in mitigating intestinal and behavioral side effects induced by PTX. Our findings suggest that interventions targeting the gut microbiota, particularly using psychobiotic compounds or their metabolites, hold promise for restoring gut health and alleviating neurological symptoms associated with dysbiosis. These insights contribute to a deeper understanding of the gut-brain axis and offer novel therapeutic strategies for improving neurological well-being.
Downloads
Downloads per month over past year
Actions (login required)
 |
Modifica documento |
